CorMedix (NASDAQ:CRMD) Stock Price Down 4.6% – Here’s What Happened

Shares of CorMedix Inc (NASDAQ:CRMD) were down 4.6% during mid-day trading on Friday . The stock traded as low as $7.70 and last traded at $7.7680. Approximately 271,047 shares traded hands during trading, a decline of 84% from the average daily volume of 1,719,592 shares. The stock had previously closed at $8.14.

CorMedix News Roundup

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix reported Q2 revenue of $101.9 million, above the roughly $96 million analyst consensus, while adjusted EBITDA reached $58.7 million and net income was $26.0 million. EPS of $0.29 also exceeded expectations. Growth was supported by continued DefenCath utilization and contributions from the Melinta portfolio. CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
• Positive Sentiment: Management maintained its FY 2026 revenue outlook of $325 million to $345 million and raised adjusted EBITDA guidance, reinforcing expectations for strong profitability and operating leverage. CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company expects to submit a supplemental filing for its fungal-disease treatment by the third quarter. Progress on this regulatory opportunity could provide an additional growth catalyst beyond DefenCath. CorMedix CEO expects supplemental filing for fungal disease treatment by Q3
• Neutral Sentiment: Brokerages currently assign CorMedix an average “Moderate Buy” recommendation, indicating generally favorable sentiment but not a uniformly bullish analyst view. CorMedix Given Average Recommendation of Moderate Buy
• Neutral Sentiment: Although the revenue outlook’s midpoint is broadly in line with consensus, investors may be taking profits or reassessing valuation after the initial earnings-driven rally. The stock remains below its 50-day moving average, adding to near-term volatility.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on CRMD shares. Needham & Company LLC upped their target price on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Leerink Partners raised their price target on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. Citizens Jmp restated a “market outperform” rating and issued a $19.00 price target on shares of CorMedix in a report on Tuesday, April 28th. Zacks Research raised shares of CorMedix from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Price Performance

The company has a market capitalization of $607.12 million, a PE ratio of 3.65 and a beta of 1.50. The company has a current ratio of 2.97, a quick ratio of 2.74 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average price is $8.16 and its 200-day moving average price is $7.65.

CorMedix (NASDAQ:CRMD) last issued its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. CorMedix had a return on equity of 45.57% and a net margin of 45.25%.The business had revenue of $101.93 million for the quarter, compared to analyst estimates of $96.04 million. On average, sell-side analysts forecast that CorMedix Inc will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CorMedix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its holdings in shares of CorMedix by 22.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after purchasing an additional 1,190 shares during the period. Gryphon Financial Partners LLC increased its position in CorMedix by 6.3% during the 1st quarter. Gryphon Financial Partners LLC now owns 27,401 shares of the company’s stock worth $186,000 after purchasing an additional 1,618 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in CorMedix by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,987 shares of the company’s stock worth $222,000 after purchasing an additional 1,631 shares in the last quarter. Financial Management Professionals Inc. purchased a new position in CorMedix in the fourth quarter valued at approximately $25,000. Finally, Comerica Bank raised its holdings in CorMedix by 454.6% in the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after buying an additional 2,205 shares during the period. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.